mdl 100240 has been researched along with enalaprilat anhydrous in 1 studies
Studies (mdl 100240) | Trials (mdl 100240) | Recent Studies (post-2010) (mdl 100240) | Studies (enalaprilat anhydrous) | Trials (enalaprilat anhydrous) | Recent Studies (post-2010) (enalaprilat anhydrous) |
---|---|---|---|---|---|
21 | 9 | 0 | 846 | 109 | 76 |
Protein | Taxonomy | mdl 100240 (IC50) | enalaprilat anhydrous (IC50) |
---|---|---|---|
Angiotensin-converting enzyme | Mus musculus (house mouse) | 0.0115 | |
Angiotensin-converting enzyme | Homo sapiens (human) | 0.2405 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.0054 | |
Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0012 | |
Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.0036 | |
Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.0024 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bennett, T; Brunner-Ferber, F; Gardiner, SM; Kemp, PA | 1 |
1 other study(ies) available for mdl 100240 and enalaprilat anhydrous
Article | Year |
---|---|
Comparative effects of the dual metallopeptidase inhibitor, MDL 100,240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen-2)27) rats.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Benzazepines; Bradykinin; Enalaprilat; Hemodynamics; Hypertension; Male; Metalloendopeptidases; Protease Inhibitors; Pyridines; Rats | 1997 |